Quantcast
Home > Quotes > ASMB

Assembly Biosciences, Inc. Common Stock (ASMB) Quote & Summary Data

ASMB 
$24.87
*  
0.48
1.97%
Get ASMB Alerts
*Delayed - data as of Dec. 12, 2018 9:52 ET  -  Find a broker to begin trading ASMB now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ASMB Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 24.15 / $ 25.62
1 Year Target
62
Today's High / Low
$ 24.87 / $ 24.61
Share Volume
922
50 Day Avg. Daily Volume
200,910
Previous Close
$ 24.39
52 Week High / Low
$ 67.36 / $ 20.61
Market Cap
633,269,088
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.41

Intraday Chart

Shares Traded

Share Volume:
922
50 Day Avg. Daily Volume:
200,910

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.13

Trading Range

The current last sale of $24.87 is 20.67% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 24.87 $ 67.36
 Low: $ 24.61 $ 20.61

Company Description (as filed with the SEC)

We are a clinical stage biotechnology company advancing two innovative platform programs: a new class of oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and a novel class of oral synthetic live biotherapeutic candidates, which are designed to treat disorders associated with the microbiome. Over 250 million people worldwide are chronically infected with HBV. Our HBV-cure program is pursuing multiple drug candidates that inhibit the HBV lifecycle and block the generation of covalently closed circular DNA (cccDNA), with the aim of increasing the current low cure rate for patients with HBV. We have discovered multiple novel Core protein Allosteric Modifiers (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein.  ... More ...  


Risk Grade

Where does ASMB fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 24.61
Open Date:
Dec. 12, 2018
Close Price:
$ 24.39
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info